Category: NxStage Medical Inc.
A list of some of the tax tabs for medical device companies for the medical device excise tax during Q1
In January 2013, Medical device companies began paying a 2.3% excise tax on U.S. Sales in order to pay for the Patient Protection and Affordable Care Act.
The levy is expected to generate some $30 billion over the next 10 years.
MassDevice.com is tracking the tally paid by several medical device companies, based on quarterly earnings report for the first quarter of 2013. We will update the list as more companies returns file in.
Tallies based on companies with Q1 earnings ended on March 31, 2013
Shares of NxStage Medical are up on news of higher 1st-quarter sales, lower losses and confirmed 2013 guidance.
NxStage Medical (NSDQ:NXTM) shares are up more than 5% today after the medical device company reported 1st-quarter sales growth and lower losses and affirmed its outlook for the rest of 2013.
U.S. healthcare regulators expand NxStage Medical's System One clearance to include high flow capabilities for home hemodialysis.
NxStage Medical (NSDQ:NXTM) touted FDA clearance for high flow capabilities for the company's System One home hemodialysis technology, a device the company calls the "only truly portable hemodialysis system cleared for home use."
The Lawrence, Mass.-based medical device maker plans to launch new higher flow System One devices later this year, according to a press release.
NxStage names Robert Funari its new chairman, following the resignation of Philippe Chambon after 15 years on the medical device company's board.
NxStage Medical (NSDQ:NXTM) named Robert Funari to replace Philippe Chambon as non-executive chairman after 15 years on the medical device company's board of directors.
Oncology diagnostics company On-Q-ity folds up its tents after an unsuccessful, 3-year bid to develop personalized cancer diagnostics – and burning through $26 million in venture capital backing.
On-Q-ity, which raised a $26 million Series A round back in December 2009, quietly folded its tents last year after an unsuccessful bid to develop its technology for personalized cancer detection.
Bruce Booth, a partner at Atlas Ventures, 1 of the VC shops that backed the company (and a member of On-Q-ity's board), detailed the reasons behind the decision this week on his blog, Life Sci VC.
Novadaq says its deal with wound care giant Kinetic Concepts Inc. for the Luna wound imaging device the companies co-developed has come to an amicable end.
Novadaq Technologies (TSE:NDQ) said it and wound care giant Kinetic Concepts agreed to an amicable end to the co-development deal they inked in 2011 for the Luna wound imaging device.
NxStage Medical founder & CEO Jeff Burbank tells MassDevice.com about its 4th-quarter and 2012 results, which topped Wall Street forecasts today, sending share prices up nearly 8% at their peak.
NxStage Medical (NSDQ:NXTM) shares jumped nearly 8% today after the medical device company reported Wall-Street-beating results for the 4th quarter and 2012.
